Kineta to Host Key Opinion Leader Event on KVA12123: VISTA as an Immuno-Oncology Target
SEATTLE, March 06, 2023 -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on developing next-generation immunotherapies to address cancer immune resistance, announced tod ...